Altimmune Exceeds Q2 EPS Expectations, Holding $183.1M in Cash Reserves

Altimmune (ALT) reported a Q2 EPS of -$0.27, beating expectations by $0.04. The company holds $183.1 million in cash, cash equivalents, and short-term investments as of June 30, 2025. Analysts project significant upside potential with an average one-year target price of $18.13, a 437.04% potential increase from the current market price of $3.38. Brokerage firms give Altimmune an "Outperform" rating based on a consensus recommendation.

Altimmune (ALT) reported its second quarter earnings, with a net loss of $0.27 per share, which beat the analyst estimate of $-0.31. The company's revenue for the quarter was $5K, falling short of the consensus estimate of $833M. Despite the financial setback, Altimmune's stock closed at $3.38, down 39.43% in the last three months and 40.89% in the last 12 months [1].

Altimmune's financial health score, as rated by InvestingPro, is "weak performance". The company holds $183.1 million in cash, cash equivalents, and short-term investments as of June 30, 2025, a 39% increase from $131.9 million at December 31, 2024 [2]. This robust cash position provides a strong financial foundation for the company's ongoing clinical trials and future development.

Analysts project significant upside potential for Altimmune, with an average one-year target price of $18.13, a 437.04% potential increase from the current market price of $3.38. Brokerage firms give Altimmune an "Outperform" rating based on a consensus recommendation [1].

Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide, Altimmune's lead product candidate, to be a highly differentiated MASH therapy. Pemvidutide demonstrated statistically significant MASH resolution and weight loss at 24 weeks, along with potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammation and fibrosis [2]. The company expects to report the full 48-week data from the IMPACT trial in the fourth quarter of 2025.

Altimmune is also advancing pemvidutide in other indications, including Alcohol Use Disorder (AUD) and Alcohol-Associated Liver Disease (ALD), with the initiation of RECLAIM and RESTORE Phase 2 trials in May and July 2025, respectively. The company's strong pipeline and promising clinical data position it well for future growth and potential regulatory approvals.

References:
[1] https://za.investing.com/news/earnings/altimmune-earnings-beat-by-004-revenue-fell-short-of-estimates-3833984
[2] https://finance.yahoo.com/news/altimmune-announces-second-quarter-2025-110000124.html